Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov ID: NCT00931385

Public ClinicalTrials.gov record NCT00931385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil Iin Patients With Chronic Obstructive Pulmonary Disease

Study identification

NCT ID
NCT00931385
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
99 participants

Conditions and interventions

Interventions

  • BI 1744 Drug
  • bi1744 Drug
  • Placebo Drug
  • Foradil Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2009
Primary completion
Mar 31, 2010
Completion
Not listed
Last update posted
Jun 30, 2014

Started 2009

United States locations

U.S. sites
11
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
1222.24.24011 Boehringer Ingelheim Investigational Site Tampa Florida
1222.24.24009 Boehringer Ingelheim Investigational Site Overland Park Kansas
1222.24.24007 Boehringer Ingelheim Investigational Site Lafayette Louisiana
1222.24.24002 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1222.24.24010 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma
1222.24.24004 Boehringer Ingelheim Investigational Site Easley South Carolina
1222.24.24006 Boehringer Ingelheim Investigational Site Gaffney South Carolina
1222.24.24005 Boehringer Ingelheim Investigational Site Greenville South Carolina
1222.24.24008 Boehringer Ingelheim Investigational Site Greenville South Carolina
1222.24.24001 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1222.24.24003 Boehringer Ingelheim Investigational Site Union South Carolina

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00931385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 30, 2014 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00931385 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →